Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
McKinsey
Mallinckrodt
Boehringer Ingelheim
Colorcon

Last Updated: January 31, 2023

CAMCEVI KIT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Camcevi Kit, and what generic alternatives are available?

Camcevi Kit is a drug marketed by Accord and is included in one NDA. There are three patents protecting this drug.

This drug has twenty patent family members in fifteen countries.

The generic ingredient in CAMCEVI KIT is leuprolide mesylate. There are twenty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the leuprolide mesylate profile page.

DrugPatentWatch® Generic Entry Outlook for Camcevi Kit

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 16, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for CAMCEVI KIT
International Patents:20
US Patents:3
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
DailyMed Link:CAMCEVI KIT at DailyMed
Drug patent expirations by year for CAMCEVI KIT
DrugPatentWatch® Estimated Generic Entry Opportunity Date for CAMCEVI KIT
Generic Entry Date for CAMCEVI KIT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
EMULSION;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for CAMCEVI KIT

CAMCEVI KIT is protected by three US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of CAMCEVI KIT is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting CAMCEVI KIT

Pharmaceutical compositions with enhanced stability
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Pharmaceutical compositions with enhanced stability
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Pharmaceutical compositions with enhanced stability
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

FDA Regulatory Exclusivity protecting CAMCEVI KIT

NEW PRODUCT
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Accord CAMCEVI KIT leuprolide mesylate EMULSION;SUBCUTANEOUS 211488-001 May 25, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Accord CAMCEVI KIT leuprolide mesylate EMULSION;SUBCUTANEOUS 211488-001 May 25, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Accord CAMCEVI KIT leuprolide mesylate EMULSION;SUBCUTANEOUS 211488-001 May 25, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Accord CAMCEVI KIT leuprolide mesylate EMULSION;SUBCUTANEOUS 211488-001 May 25, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for CAMCEVI KIT

When does loss-of-exclusivity occur for CAMCEVI KIT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 07207618
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 0706558
Estimated Expiration: See Plans and Pricing

Canada

Patent: 37569
Estimated Expiration: See Plans and Pricing

China

Patent: 1400363
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 84009
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 84009
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 26975
Estimated Expiration: See Plans and Pricing

Japan

Patent: 42415
Estimated Expiration: See Plans and Pricing

Patent: 09523798
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 08009125
Estimated Expiration: See Plans and Pricing

Russian Federation

Patent: 27383
Estimated Expiration: See Plans and Pricing

Patent: 08129201
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 84009
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1728868
Estimated Expiration: See Plans and Pricing

Patent: 080089643
Estimated Expiration: See Plans and Pricing

Patent: 150017777
Estimated Expiration: See Plans and Pricing

Spain

Patent: 97712
Estimated Expiration: See Plans and Pricing

Taiwan

Patent: 76241
Estimated Expiration: See Plans and Pricing

Patent: 0831131
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering CAMCEVI KIT around the world.

Country Patent Number Title Estimated Expiration
Taiwan 200831131 Pharmaceutical compositions with enhanced stability See Plans and Pricing
China 101400363 Pharmaceutical compositions with enhanced stability See Plans and Pricing
European Patent Office 1984009 COMPOSITIONS PHARMACEUTIQUES A STABILITE AMELIOREE (PHARMACEUTICAL COMPOSITIONS WITH ENHANCED STABILITY) See Plans and Pricing
Russian Federation 2427383 ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ С ПОВЫШЕННОЙ СТАБИЛЬНОСТЬЮ (HIGH STABILITY PHARMACEUTICAL COMPOSITIONS) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
AstraZeneca
Johnson and Johnson
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.